MediciNova, Inc.  

(Public, NASDAQ:MNOV)   Watch this stock  
Find more results for MNOV
4.00
+0.06 (1.52%)
May 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.83 - 4.00
52 week 1.72 - 5.90
Open 3.94
Vol / Avg. 59,998.00/329,701.00
Mkt cap 97.33M
P/E     -
Div/yield     -
EPS -0.38
Shares 24.62M
Beta 0.83
Inst. own 10%
Jun 12, 2015
MediciNova Inc Annual Shareholders Meeting (Estimated) - 3:30PM EDT - Add to calendar
Jun 11, 2015
MediciNova Inc Annual Shareholders Meeting Add to calendar
May 6, 2015
Q1 2015 MediciNova Inc Earnings Release (Estimated) Add to calendar
Mar 13, 2015
Q4 2014 MediciNova Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -34.69% -32.37%
Return on average equity -42.45% -38.77%
Employees 10 -
CDP Score - -

Address

SUITE 650, 4275 EXECUTIVE SQUARE
LA JOLLA, CA 92037
United States - Map
+1-858-3731500 (Phone)
+1-858-4040048 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medicinova Inc. is a biopharmaceutical company. The Company is focused on developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. The Company is also focusing its development activities on MN-166 (Ibudilast) for the treatment of neurological disorders, MN-221 (Bedoradrine) for the treatment of acute exacerbations of asthma, MN-001 (Tipelukast) for the treatment of NASH (nonalcoholic steatohepatitis), and MN-029 (Denibulin) for the treatment of solid tumors.

Officers and directors

Jeffrey Himawan Ph.D. Independent Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Yuichi Iwaki M.D., Ph.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Esther van den Boom Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Age: 34
Bio & Compensation  - Reuters
Geoffrey G. O'Brien J.D. Vice President
Age: 45
Bio & Compensation  - Reuters
Masatsune Okajima Vice President, Head - Japanese Office
Age: 46
Bio & Compensation  - Reuters
Kazuko Matsuda M.D., Ph.D. Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
Yoshio Ishizaka Director
Bio & Compensation  - Reuters
Yutaka Kobayashi Director
Age: 50
Bio & Compensation  - Reuters
Kousuke Nakata CPA Director
Age: 41
Bio & Compensation  - Reuters
Hiroaki Shigeta Independent Director
Age: 71
Bio & Compensation  - Reuters